Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Inclusion Criteria: * Male and female subjects with mild to moderate facial SD (IGA 2 or 3), ≥18 years of age, inclusive. The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than SD following a detailed medical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, virology and urinalysis; * Confirmed SD diagnosis by dermatologist * Significant facial SD affected area as judged by the investigator or medically qualified designee * Able to participate and willing to give written informed consent and to comply with the study restrictions; * Willing to refrain from using other SD treatments in the local treatment area * Subjects and their partners of childbearing potential must use effective contraception, for the duration of the study and for 3 months after the last dose. Exclusion Criteria: * Any current and / or recurrent clinical significant skin condition other than SD; * Ongoing use of prohibited SD medication. Washout periods prior to baseline are as follows; 1. Topical steroids, antibiotics, antifungals or other topical (OTC) therapies: 2 weeks 2. Systemic steroids, antibiotics, antifungals or other systemic therapies: 4 weeks; 3. Phototherapy: 3 weeks; 4. Regular use of shampoo for the treatment of PC (including but not limited to OTC zinc pyrithione shampoo), soap for the treatment of seborrheic dermatitis: 2 weeks 5. Changing a soap, method for daily facial and hair washing: 1 week * Known hypersensitivity to the compounds or excipients of the compounds; * Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrollment; * Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding; * Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times in the past year; * Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.